Bicycle Therap

$26.40 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Bicycle Therap

Bicycle Therapeutics PLC, formerly Bicycle Therapeutics Limited, is a clinical-stage biopharmaceutical company. The Company is focused on developing a class of medicines for diseases. The Company’s lead product candidate, BT1718, is a Bicycle Toxin Conjugate (BTC) for oncology indications. BT1718 targets tumors that express Membrane Type 1 matrix metalloprotease (MT1-MMP). The Company is also developing BT5528 and BT8009, which are BTCs targeting Ephrin type-A receptor 2 (EphA2), and Nectin-4, for oncology indications. The Company is also developing cytotoxic T-cell activators, designed to trigger an immune response to tumors.

Stock Analysis

last close $26.25
1-mo return 28.4%
3-mo return 57.8%
avg daily vol. 216.97T
52-week high 62.08
52-week low 12.08
market cap. $779M
forward pe -
annual div. -
roe -38.7%
ltg forecast -
dividend yield -
annual rev. $16M
inst own. 82.6%

Subscribe now for daily local and international financial news